Why the study?
Endocardial pacing may benefit patients failing to improve after conventional epicardial CRT, but whether the wireless WiSE-CRT system improves symptoms or LV remodeling in nonresponders required evaluation.
Does leadless left ventricular endocardial pacing improve symptoms and LV remodeling in patients who are nonresponders to conventional CRT?
Does leadless left ventricular endocardial pacing improve symptoms and LV remodeling in patients who are nonresponders to conventional CRT?
The WiSE-CRT system for leadless LV endocardial pacing offers a viable treatment option that improves electrical synchrony and LVEF in patients who fail to respond to conventional epicardial CRT.
May support endocardial CRT feasibility in nonresponders; leaves open need for randomized efficacy and safety data.
Background Endocardial pacing may be beneficial in patients who fail to improve following conventional epicardial cardiac resynchronization therapy (CRT). The potential to pace anywhere inside the left ventricle thus avoiding myocardial scar and targeting the latest activating segments may be particularly important. The WiSE‐CRT system (EBR systems, Sunnyvale, CA) reliably produces wireless, endocardial left ventricular (LV) pacing. The purpose of this analysis was to determine whether this system improved symptoms or led to LV remodeling in patients who were nonresponders to conventional CRT. Method An international, multicenter registry of patients who were nonresponders to conventional CRT and underwent implantation with the WiSE‐CRT system was collected. Results Twenty‐two patients were included; 20 patients underwent successful implantation with confirmation of endocardial biventricular pacing and in 2 patients, there was a failure of electrode capture. Eighteen patients proceeded to 6‐month follow‐up; endocardial pacing resulted in a significant reduction in QRS duration compared with intrinsic QRS duration (26.6 ± 24.4 ms; P = .002) and improvement in left ventricular ejection fraction (LVEF) (4.7 ± 7.9%; P = .021). The mean reduction in left ventricular end‐diastolic volume was 8.3 ± 42.3 cm 3 ( P = .458) and left ventricular end‐systolic volume (LVESV) was 13.1 ± 44.3 cm 3 ( P = .271), which were statistically nonsignificant. Overall, 55.6% of patients had improvement in their clinical composite score and 66.7% had a reduction in LVESV ≥15% and/or absolute improvement in LVEF ≥5%. Conclusion Nonresponders to conventional CRT have few remaining treatment options. We have shown in this high‐risk patient group that the WiSE‐CRT system results in improvement in their clinical composite scores and leads to LV remodeling.
No takes yet. Share an insight, caveat, or question.
Sidhu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: